Nearly half of patients with Parkinson disease (PD) who experience anxiety symptoms report anxiety-related activity limitations, which is associated with an increased likelihood of seeking treatment. These are the findings of a study presented at the 2025 American Academy of Neurology (AAN) annual meeting, held from April 5 to 9, 2025, in San Diego, California, and published in the journal Neurology.
Anxiety is a common nonmotor symptom in PD; however, how anxious symptoms affect activity limitations and whether they affect treatment-seeking behaviors is not fully understood.
Researchers from Rutgers New Jersey Medical School in the United States conducted this case-control study using questionnaire data from the Fox Insight Data Exploration Network. Patients (N=31,124) with PD who responded to a survey about symptoms of anxiety and related activity limitations and treatments were included in this study.
Nearly a third of patients (32.6%) reported symptoms of anxiety.
Among individuals with comorbid anxiety, 43.9% reported having activity limitations due to anxious symptoms.
Among individuals who reported anxiety-related activity limitations, nearly three-quarters (74.6%) reported receiving treatment for their anxiety.
Having a diagnosis of PD was associated with an increased likelihood of having comorbid anxiety (odds ratio [OR], 1.22; 95% CI, 1.12-1.32). Having PD and anxiety-related activity limitations was associated with an increased likelihood of seeking treatment for anxious symptoms (OR, 1.65; 95% CI, 1.52-1.79).
This study was limited by relying on self-reported symptoms and treatment behaviors.
“Assessing anxiety severity in individuals with PD is important for treatment potential and understanding contributors to functional limitations of the disease,” the researchers concluded.
May 30, 2025
May 23, 2025
May 5, 2025
April 25, 2025
April 21, 2025
April 21, 2025
References:
Acquaviva J, Terrizzi J, Xu Y, et al. Parkinson disease and anxiety: activity limitation and treatment opportunities (P7-5.029). Neurology. 2025;104(7_Supplement_1). doi:10.1212/WNL.0000000000212533
